Australis Capital Inc.

AUSA

CA05259R1073

Pharmaceuticals

Delayed Canadian Securities Exchange Other stock markets 15:54:46 2022-10-18 EDT			5-day change	1st Jan Change
0.025 ^CAD	+25.00%		-.--%	-.--%

2023	Australis Capital Inc. Appoints Robert Wilson as Its New CFO	CI
2022	Australis Capital Inc. Announces Executive Changes	CI

Australis Capital Inc. Appoints Sameer Kumar as Independent Member of its Board of Directors

September 28, 2020 at 07:00 am

Australis Capital Inc. announced the appointment of Sameer Kumar as an independent member of its Board of Directors.

Latest news about Australis Capital Inc.

Australis Capital Inc. Appoints Robert Wilson as Its New CFO	23-04-11	CI
Australis Capital Inc. Announces Executive Changes	22-12-19	CI
Australis Capital Inc Completes Final New Jersey License Application Step	22-11-10	CI
Australis Capital Inc. Announces Board Changes	22-08-08	CI
Australis Capital Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	22-08-02	CI
Australis Capital Inc. Enters into Credit Facility with Lola Ventures	22-07-29	CI
Australis Capital Inc. Completes Submission to the City of Millville, New Jersey	22-07-20	CI
Australis Capital Inc. Appoints Jill Swainson as Member of Board of Directors	22-07-05	CI
Australis Capital Inc. Enters into an Agreement with Hempire Farms, LLC	22-06-23	CI
Australis Capital Inc. Announces Mr. Natural, an AUDACIOUS Brand, Launched Its First Product in Nevada: Full Spectrum Hash RSO	22-04-25	CI
Australis Capital Inc. Collaborates with the Black Institute Group	22-04-20	CI
Australis Capital Inc. Receives Provisional Cultivation License, as Well as A Provisional Manufacturing License in the State of New Jersey	22-04-19	CI
AUDACIOUS and Golden Triangle Health Partner to Open the First Herbidus Medical Center in Bangkok	22-03-21	CI
Transcript : Australis Capital Inc., Q3 2022 Earnings Call, Mar 02, 2022	22-03-02
Australis Capital Inc. entered into an agreement to acquire a 51% stake in Belle Fleur Manufacturing Facility in Massachusetts.	22-02-28	CI
Australis Capital Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-28	CI
Australis Capital Inc. completed the acquisition of Gary Maverick Inc. for $0.5 million.	22-01-12	CI
Audacious Enters into Definitive Agreement with Golden Triangle Health	22-01-12	CI
Transcript : Australis Capital Inc. - Shareholder/Analyst Call	21-12-17
AUDACIOUS to Enter New York Cannabis Market Through Partnership with First Americans, LLC	21-12-14	CI
Australis Capital Inc. announced that it expects to receive CAD 20 million in funding from LDA Capital Limited	21-12-08	CI
Australis Capital Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-23	CI
Transcript : Australis Capital Inc., Q2 2022 Earnings Call, Nov 23, 2021	21-11-23
Playtertainment, Inc. announced that it has received $5 million in funding from Australis Capital Inc., Sharp Alpha Advisors, LLC, and other investors	21-11-08	CI
AUDACIOUS Signs Term Sheet with Golden Triangle Health to Drive Entry into the Asia-Pacific Cannabis Market	21-11-03	CI

Australis Capital Inc. is a multi-state operator in the cannabis industry in the United States. The Company is involved in the cannabis and horticultural industries in the United States and abroad. It is focused on brands and cannabis licenses in states with favorable economics. The Company also operates an engineering consulting firm. The Company advises on greenhouse design, build and operations throughout the world in cannabis and horticulture. Its operations range from providing sustainable cultivation design and optimization to retail storefronts, growing flowers in-house, and manufacturing brand, AUDACIOUS has products and solutions for everyone.

Sector

Pharmaceuticals

More about the company

Sector Alternative Medicine

	1st Jan change	Capi.
AUSTRALIS CAPITAL INC.	-.--%	6.4M
DONG-E-E-JIAO CO.,LTD.	+39.27%	6.07B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-18.60%	4.42B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+3.27%	3.26B
TASLY PHARMACEUTICAL GROUP CO., LTD	-15.69%	3B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-5.88%	2.47B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+43.78%	1.89B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-11.89%	1.63B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-4.67%	1.6B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-14.39%	1.54B

Alternative Medicine